Navigation Links
Signalife Announces Anticipated Date of Transition to OTCBB

LOS ANGELES, Sept. 8 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) announced that it has filed its Form 25 with the Securities and Exchange Commission effecting the withdrawal of trading of its common stock on the American Stock Exchange ("AMEX"). The last day that Signalife's common stock will trade on AMEX will be Friday, September 12, 2008. Signalife expects that the company's common stock will be available for quotation on both the Over-The-Counter Bulletin Board and the Pink Sheets commencing upon the opening of market on Monday, September 15, 2008. Pursuant to OTCBB policy, it will assign a new trading symbol for Signalife's common stock following the close of trading on AMEX on Friday, September 12, 2008. Signalife will publicly announce the new trading symbol promptly upon receipt from the OTCBB.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. More information is located at Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, the failure of Signalife's market maker to complete or timely complete the process of qualifying the shares for quotation on the OTCBB, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology and procure market acceptance for these products, failure to obtain federal or state or governmental or international regulatory approvals governing heart monitoring and other biomedical devices incorporating the technology, failure to obtain import and export capabilities in the various countries containing buyers and resellers and hospitals and clinics and doctors for the devices, inability to obtain physician, patient or insurance acceptance of or for heart monitoring and other biomedical incorporating of the technologies, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical and information solutions incorporating the companies' technologies. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Provides Corporate Update
2. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Signalife Receives Another $3.3 Million Sales Orders
6. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
7. Signalife Continues to Procure Purchase Orders, Revenues
8. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
9. U.S. Patent 7,299,083 Awarded to Signalife
10. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
11. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Researchers at the ... Institute for Brain Research at MIT have engineered changes ... cut down on "off-target" editing errors. The refined technique ... use of genome editing. Science , ... three of the approximately 1,400 amino acids that make ...
(Date:12/1/2015)... VIEW, Calif. , Dec. 1, 2015 /PRNewswire/ ... the Transformational Health program. This program addresses ways ... period of change. ... Logo - ... every aspect of healthcare, as well as the ...
(Date:12/1/2015)... ROSEVILLE, Minn. , Dec. 1, 2015  The ... the recipient of the 2015 Tekne Award in the ... th at the Minneapolis ... who have played a significant role in developing new ... people living around the world. Clostridium difficile ...
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
Breaking Biology Technology:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific discoveries ... doctors and other healthcare providers face challenges in better ... and patients. In addition, as more children continue to ... patient,s adulthood and old age. John M. ... Children,s Hospital of Philadelphia (CHOP) . --> ...
Breaking Biology News(10 mins):